Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. ESTCAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets.Akebia will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please registe ...

Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo® (vadadustat) for ...

U.S. Renal Care is a leading provider of in-center and home dialysis in the United StatesCAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. The contract enables USRC attending physicians ...

Core Insights - Akebia Therapeutics and U.S. Renal Care are initiating a clinical trial for Vafseo to assess its impact on mortality and hospitalization in patients with chronic kidney disease [1][2] - The VOICE trial aims to enroll approximately 2,200 patients, comparing Vafseo to standard erythropoiesis-stimulating agents [2] - The trial's primary endpoint is all-cause mortality, while the secondary endpoint focuses on all-cause hospitalization, with a goal of demonstrating non-inferiority for mortality and superiority for hospitalization reduction [2][3] Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [4] - U.S. Renal Care is the largest privately held dialysis provider in the U.S., serving over 36,000 patients across 32 states since its establishment in 2000 [5] Product Information - Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoietin production to manage anemia in chronic kidney disease patients on dialysis [6][7] - Vafseo is approved for use in 37 countries and is indicated for adults receiving dialysis for at least three months [6][7] Clinical Trial Details - The VOICE trial will randomize patients to receive either oral Vafseo 300 mg three times per week or standard care agents, concluding approximately 18 months after the last patient is enrolled [2] - The trial is designed to provide real-world evidence regarding the safety and efficacy of Vafseo in alignment with patients' dialysis schedules [3]

Akebia Therapeutics (AKBA) has seen its share price rise after it gained FDA approval for Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in late March this year.The approval of Vafseo tablets gave this Zacks Rank #2 (Buy) company its second FDA-approved product after Auryxia (ferric citrate), which is indicated for the control of serum phosphorus levels in adult patients with CKD on dialysis. The oral method of the use of Vafseo tablets makes it an easier-to-use ...

The Zacks Medical-Drugs industry is showing promising trends in 2024 amid strong M&A activity and positive pipeline news. Concerns around the economy and inflation, regular pipeline setbacks, uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s (FTC) scrutiny of M&A deals are some of the headwinds faced by drug/biotech companies.However,innovation is at its peak for the industry, with key spaces like diabetes/obesity, inflammation and neuroscience attracting at ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - President and Chief Executive Officer Nicholas Grund - Senior Vice President, Chief Commercial Officer Erik Ostrowski - Senior Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Thank you for standing by. My name is And ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisd ...

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Corporate Updates • Vafseo (vadadustat) Tablets market availability on track for January 2025 ® • TDAPA application submission and WAC pricing announcement for Vafseo complete • Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million • In June, Akebia submitted its Transitional Drug Add-on Payment Adjustment (TDAPA) application. Akebia expects to have Healthcare Common Pr ...